Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 or under any sublicense agreement as Confidential Information of Licensee as set forth in Article 8, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
Appears in 2 contracts
Samples: Collaboration Agreement (Celldex Therapeutics, Inc.), Collaboration Agreement (Curagen Corp)
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 or under any sublicense agreement as Confidential Information of Licensee as set forth in Article 8, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have [***] Confidential treatment has been filed separately requested with the Secretary of the Commission pursuant respect to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934omitted portions.
Appears in 2 contracts
Samples: Collaboration Agreement (Seattle Genetics Inc /Wa), Collaboration Agreement (Seattle Genetics Inc /Wa)
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 or under any sublicense agreement as Confidential Information of Licensee as set forth in Article 8, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
Appears in 2 contracts
Samples: Collaboration Agreement (Progenics Pharmaceuticals Inc), Collaboration Agreement (Seattle Genetics Inc /Wa)
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 or under any sublicense agreement as Confidential [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Information of Licensee as set forth in Article 8, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
Appears in 1 contract
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 or under any sublicense agreement as Confidential Information of Licensee as set forth in Article 8, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of [***] Certain information on this Exhibit were page has been omitted and have been filed separately with the Secretary of the Commission pursuant Securities and Exchange Commission. Confidential treatment has been requested with respect to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934omitted portions.
Appears in 1 contract
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 8 or under any sublicense agreement as Confidential Information of Licensee GNE as set forth in Article 89, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 19349.
Appears in 1 contract
Confidential Financial Information. SGI shall treat all financial information subject to review under this Article 7 8 or under any sublicense agreement as Confidential Information of Licensee as set forth in Article 8Celltech, and shall cause its accounting firm to retain all such financial information in confidence under terms substantially similar to those set forth in Article 8. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934confidence.
Appears in 1 contract